Kereiakes DJ, Ellis SG, Metzger DC, et al. - Given that bioresorbable vascular scaffold (BVS) vs cobalt chromium everolimus-eluting stents (EES) offered non-inferior rates of target lesion failure (cardiac death, target vessel myocardial infarction [TVMI] or ischemia-driven target lesion revascularization) at 1 year in the ABSORB III trial, and increased adverse event rates (particularly TVMI and scaffold thrombosis) were reported following BVS between 1 year and 3 years, and cumulative to 3 years, therefore, researchers evaluated 5-year clinical outcomes post-BVS, including beyond the 3-year time point of complete scaffold resorption. They examined clinical results from ABSORB III via randomized device (intention-to-treat) cumulative to 5 years and between 3-5 years. Findings of the ABSORB III trial revealed increased cumulative 5-year adverse event rates following BVS vs EES. However, the period of excess risk for BVS ceased at 3 years coincident with complete scaffold resorption.